Shares of Iterum Therapeutics PLC (NASDAQ:ITRM) have received a consensus rating of “Buy” from the six analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $18.00.
A number of equities analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Iterum Therapeutics in a report on Thursday, August 15th. Zacks Investment Research raised shares of Iterum Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 17th. Finally, ValuEngine raised shares of Iterum Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, October 4th.
ITRM opened at $4.33 on Wednesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.10 and a quick ratio of 2.10. The company’s 50 day moving average is $6.09 and its 200 day moving average is $6.91. Iterum Therapeutics has a 12-month low of $4.07 and a 12-month high of $9.30.
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Recommended Story: How dollar cost averaging works
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.